口腔粘膜下纤维性变
肌成纤维细胞
癌症研究
纤维化
医学
靶向治疗
恶性转化
癌症
嵌合抗原受体
免疫系统
免疫学
成纤维细胞
伤口愈合
T细胞
病理
生物
内科学
细胞培养
遗传学
作者
Sachin C. Sarode,Nilesh Kumar Sharma,Gargi S Sarode,Mohit Sharma,Raghu Radhakrishnan
标识
DOI:10.1016/j.mehy.2022.110897
摘要
Despite several advancements in understanding the pathogenesis of oral submucous fibrosis (OSMF), there is no definitive therapy for the complete remission of the disease process. This is attributed to the fact that any chronic fibrotic disease targeting myofibroblasts, the primary cells responsible for fibrosis is challenging. The betel quid-associated chemicals, predominantly, arecoline and arecaidine, advance the activation of resident fibroblasts to myofibroblasts in OSMF, resulting in uncontrolled and excessive production of collagen. The myofibroblasts, which are associated with the malignant transformation express fibroblast-activating protein (FAP) on their surface that could be selectively targeted for the treatment of OSMF. In the present paper, we propose that the adoptive transfer of T cells that express a chimeric antigen receptor against fibroblast activation protein (FAP CAR T cell therapy) results in a significant reduction in fibrosis and restoration of function in OSMF. The detailed procedural aspects of this therapy along with experimental designs are also discussed. Since myofibroblasts are involved in the malignant transformation of OSMF, the selective elimination of these cells will reduce the cancer development and ultimately the cancer burden.
科研通智能强力驱动
Strongly Powered by AbleSci AI